Print Page  |  Close Window

SEC Filings

8-K
TEVA PHARMACEUTICAL INDUSTRIES LTD filed this Form 8-K on 02/08/2018
Entire Document
 

   
Reconciliation of our segment profit
to consolidated income before income taxes
 
Three months ended December 31,
2017 2016
Unaudited, U.S.$ in millions
Generic medicines profit $ 740 $ 1,075
Specialty medicines profit   981   1,124
Total segment profit 1,721 2,199
Profit of other activities   25   40
Total profit 1,746 2,239
Amounts not allocated to segments:
Amortization 356 182
General and administrative expenses 492 360
Other asset impairments, restructuring and other items 3,865 998
Goodwill impairment 11,000 900
Inventory step-up - 140
Other R&D expenses 45 164
Costs related to regulatory actions taken in facilities (1) 30
Legal settlements and loss contingencies 176 225
Venezuela deconsolidation charge 396 -
Gain on sales of business (1,083) (27)
Other unallocated amounts (1) (483) (596)
   
Consolidated operating loss (13,017) (137)
Financial expenses - net 191 777
Consolidated loss before income taxes $ (13,208) $ (914)
(1) Includes for 2016, $133 million in inventory related-expenses in connection with the devaluation in Venezuela.